MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
47.63
-0.90
-1.85%
After Hours: 47.63 0 0.00% 16:33 07/18 EDT
OPEN
48.88
PREV CLOSE
48.53
HIGH
49.09
LOW
47.23
VOLUME
628.56K
TURNOVER
--
52 WEEK HIGH
58.38
52 WEEK LOW
29.02
MARKET CAP
3.78B
P/E (TTM)
7.33
1D
5D
1M
3M
1Y
5Y
1D
PTC Therapeutics Advances Long-Term Study on Vatiquinone for Friedreich Ataxia
TipRanks · 1d ago
CFO’s Strategic Move: Major Stock Sale at PTC Therapeutics!
TipRanks · 1d ago
CFO Pierre Gravier Reports Disposal of PTC Therapeutics Inc. Common Shares
Reuters · 1d ago
PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors
TipRanks · 2d ago
PTC Therapeutics Advances PKU Treatment with Sepiapterin Study
TipRanks · 2d ago
PTC Therapeutics’ Vatiquinone Study: A Long-Term Commitment to Friedreich Ataxia
TipRanks · 3d ago
Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)
TipRanks · 3d ago
UBS Keeps Their Buy Rating on PTC Therapeutics (PTCT)
TipRanks · 4d ago
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.